Panitumumab

Drug Profile

Panitumumab

Alternative Names: ABX-EGF; Anti-EGFR monoclonal antibody - Abgenix; E7.6.3; rHuMAb-EGFr; Vectibix

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Takeda; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase II Bladder cancer; Breast cancer; Neuroendocrine tumours
  • Phase I Solid tumours
  • Discontinued Head and neck cancer; Malignant melanoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 02 Mar 2017 National Institute for Health and Care Excellence (NICE) recommends panitumumab for metastatic colorectal cancer for previously untreated patients
  • 01 Dec 2016 Amgen initiates enrolment in the phase II UCGI28_PANIRINOX trial for Colorectal cancer (Combination therapy, Metastatic disease) in France (NCT02980510)
  • 29 Nov 2016 Updated results from the phase III ASPECCT trial in Colorectal cancer presented at the 28th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top